Gyre Therapeutics
GYRE
35 hedge funds and large institutions have $3.9M invested in Gyre Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 9 closing their positions.
64,800% more call options, than puts
Call options by funds: $1.3M | Put options by funds: $2K
0.13% less ownership
Funds ownership: 3.4% → 3.28% (-0.13%)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
15% less funds holding
Funds holding: 41 → 35 (-6)
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
73% less capital invested
Capital invested by funds: $14.2M → $3.9M (-$10.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$944K |
| 2 |
Renaissance Technologies
New York
|
+$515K |
| 3 |
VF
Virtu Financial
New York
|
+$229K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$82.2K |
| 5 |
Lazard Asset Management
New York
|
+$77.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAP
Madison Avenue Partners
New York
|
-$1.79M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$341K |
| 3 |
EWM
Essex Woodlands Management
The Woodlands,
Texas
|
-$140K |
| 4 |
RC
RBF Capital
San Francisco,
California
|
-$51.3K |
| 5 |
Goldman Sachs
New York
|
-$47.1K |
GYRE Hedge Fund Activity: Q3 2022 in Review
35 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q3 2022, worth a combined $3.9M — down 73% from $14.2M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of GYRE and 3 opened new positions — a net loss of 6 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was Millennium Management, adding an estimated $944K. The largest seller was Madison Avenue Partners, exiting entirely with an estimated $1.79M sold.
- 35 institutional investors held Gyre Therapeutics (GYRE) as of Q3 2022, down from 41 in Q2 2022.
- Funds reported $3.9M of Gyre Therapeutics stock for Q3 2022, down 73% quarter-over-quarter.
- 3 funds opened new Gyre Therapeutics positions in Q3 2022 and 9 closed out, a net change of -6 holders.
- The largest Gyre Therapeutics buyer in Q3 2022 was Millennium Management, an estimated $944K added.
- The largest Gyre Therapeutics seller in Q3 2022 was Madison Avenue Partners, an estimated $1.79M sold.
Based on aggregated 13F filings for Q3 2022.